Home
Site Map
About Roche
Contact Us
Help
Clinical. Credible. Convenient.
Not a Member?
Log In
Forgot Password?
Instant Access Code
Sign Up
»
E-mail:
Password:
Code:
Remember Me
Log In
»
Go
»
Main Menu
Osteoporosis Home
News
Clinical Trials
Education
Product Information
BONIVA (ibandronate sodium)
Publications
Resources
More Therapeutic Areas
Select an Area
Hepatology
HIV
Influenza
Oncology
Rheumatoid Arthritis
More Roche Product Info
Select a Product
Boniva
Fuzeon
Kytril
Invirase
Pegasys
Tamiflu
Xeloda
Other Roche Products
Meeting Calendar
Select a link below to view details.
July 2008
S
M
T
W
T
F
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Tell us what you think »
Search RocheExchange
Please use TWO or more words to qualify your search.
Example: What are the most common adverse events with Boniva?
Search
»
Osteoporosis Publications
Download Acrobat Reader »
Ibandronate Sodium Publications
Other Publications
Publication Search
Display by:
Publication date
Author
Alphabetical by Publication Title
Steven T. Harris, William A. Blumentals and Paul D. Miller
Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies
Current Medical Research and Opinion 2008 24(1): 237 - 245
Delmas PD, Adami S, Strugala C
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the Dosing Intravenous Administration study.
Arthritis and Rheumatism. 2006 54(6): 1838 - 1846
Reginster J-Y, Adami S, Lakatos P
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
Ann Rheum Dis. 2006 65(): 654 - 661
Reginster JY, Wilson KM, Dumont E
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
J Clin Endocrin Metab. 2005 90(9): 5018 - 5024
Miller PD, McClung MR, Macovei L
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from MOBILE study.
J Bone Miner Res. 2005 20(8): 1315 - 1322
Chesnut III CH, Skag A, Christiansen C
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
J Bone Miner Res. 2004 19(8): 1241 - 1249
McClung M, Wasnich R, Recker R
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
J Bone Miner Res. 2004 19(1): 11 - 18
Tanko LB, McClung MR, Schimmer RC
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
Bone 2003 32(): 421 - 426